Cargando…
EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
Cancers of the head and neck and of the lung are associated with high morbidity and mortality rates that have remained relatively unchanged for more than 3 decades, despite advances in radiation therapies and chemotherapies over the same time. It is generally believed that the efficacy of standard t...
Autores principales: | Sattler, Martin, Abidoye, Oyewale, Salgia, Ravi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
TheScientificWorldJOURNAL
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848684/ https://www.ncbi.nlm.nih.gov/pubmed/18836658 http://dx.doi.org/10.1100/tsw.2008.117 |
Ejemplares similares
-
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021) -
Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets
por: Saada-Bouzid, Esma, et al.
Publicado: (2019) -
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
por: Agulnik, Mark
Publicado: (2012) -
Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma
por: Lapidot, Moshe, et al.
Publicado: (2022) -
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)